Annual Drug Patent Expirations for HALAVEN
Halaven is a drug marketed by Eisai Inc and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug.
Drug patent litigation for HALAVEN.
The generic ingredient in HALAVEN is eribulin mesylate. Two suppliers are listed for this compound. Additional details are available on the eribulin mesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
